Drug improves survival of colorectal cancer patients, trial results show

	Tweet

An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

“For years, patients with metastatic colorectal cancer have faced a devastating impasse when standard chemotherapies have failed to halt the growth of tumors and physicians have run out of effective drugs to offer them,” says Dr. Grothey. “This is the first novel agent in eight years to show improvement in overall survival of colon cancer patients who have run out of treatment options.”

Researchers tested regorafenib in a phase III, randomized, placebo-controlled trial, conducted simultaneously in the United States, Europe, Japan, Australia and China. They looked at survival outcomes in 760 patients whose cancer had progressed despite standard chemotherapy regimens. Regorafenib is a multi-kinase inhibitor, which has the effect of slowing cell proliferation and blood vessel growth and tempering a variety of biological pathways that are activated in tumors.

Researchers found that patients with metastatic colon cancer who were treated with the drug showed a 29 percent increase in overall survival when compared to those treated with placebo. The median length of survival for patients treated with the drug increased from 5 months to 6.5 months, a statistically significant jump. Overall, regorafenib reduced patients’ risk of dying from cancer during the trial by 23 percent.

The trial, whose largest group of study participants in the United States was at Mayo Clinic, finished more than a year ahead of schedule.

“Patients with metastatic colorectal cancer who have failed all approved standard therapies have a poor prognosis,” says Dr. Grothey. “This is the first and only agent in this setting that has demonstrated statistically significant overall survival benefit.”

###

Other Mayo Clinic researchers included Daniel Sargent, Ph.D. Dr. Grothey’s research was sponsored by Bayer Healthcare.

###

Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

RELATED STORIES:
Particular experimental therapy not more effective than standard treatment for anal canal cancer   Race affects regional colorectal cancer screening disparities   Curry compound may prevent colon cancer   How Diarrheal Bacteria Cause Some Colon Cancers   Diet, smoking, exercise key in colon cancer risk   Researchers discover genes involved in colorectal cancer   Obesity tied to poorer colon cancer survival   Vitamin B6 may reduce colon cancer risk in women   Obesity hurts recovery after colon cancer surgery   US cancer deaths down but far too few Americans screened for colon cancer   Cigarette smoking linked with rectal cancer risk   The cellular root of colorectal cancers?   Chemical changes may help detect colon cancer early   Sticking to diet advice cuts colon cancer risk   Confirmation that vitamin D acts as a protective agent against the advance of colon cancer   Colorectal Cancer Screening Rates Still Too Low   CT scans may predict survival in colorectal cancer   ‘Cross-talk’ Mechanism Contributes to Colorectal Cancer   Protein Levels Indicate Risk of Death in Some Colorectal Cancer Patients   Researchers Find Four Biomarkers Important in Colerectal Cancer Treatment Prognosis   Chinese most prone to colorectal cancer in Asia   Mail and Electronic Reminders May Increase Colon Cancer Screening

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]